Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $261 from $255 and keeps an Overweight rating on the shares after the company posted a Q3 beat and raised 2025 revenue and EPS guidance. The company’s key immunology products Skyrizi and Rinvoq “continue to deliver,” while aesthetics and Humira remain soft, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Ironwood jumps after AbbVie reports Linzess sales beat
- AbbVie Stock (ABBV) Wobbles as Humira Sales Take a Hit, Dims Q3 Glow
- Midday Fly By: Apple, Amazon upbeat reports lift Nasdaq
- AbbVie’s Strong Financial Performance and Growth Potential Justifies Buy Rating
- AbbVie expects strong company growth in 2026 despite Humira erosion